Pipeline
DC-Exosome
Dendritic cell (DC)-derived exosomes are a next-generation cell-free immunotherapy platform with the potential to modulate immune responses, enhance antigen presentation, and stimulate targeted anti-tumor or regenerative effects. These nanosized extracellular vesicles carry bioactive molecules, including proteins, nucleic acids, and lipids, which contribute to their unique therapeutic properties. By harnessing the immunostimulatory potential of DC-derived exosomes, we aim to develop novel treatments for a range of diseases with high unmet medical needs.
Program
Indication
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
JY-DEX001
Undisclosed
JY-DEX001 (Undisclosed)
Program
Indication
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
JY-DEX001
Undisclosed
JY-DEX001 is our investigational DC-derived exosome therapy currently under development for an undisclosed indication. This program is part of our strategic efforts to advance cutting-edge exosome-based therapeutics that leverage the immune-modulating and regenerative capabilities of dendritic cells. The aim of JY-DEX001 is to utilize the powerful bioactive cargo of dendritic cell-derived exosomes to modulate disease pathways, enhance immune responses, and provide targeted therapeutic benefits. This therapy is designed to offer a novel, cell-free approach to treatment, with potential applications across oncology, immunology, and regenerative medicine. Preclinical research is ongoing to evaluate the safety, mechanism of action, and therapeutic efficacy of JY-DEX001. As we progress towards clinical development, further details regarding the specific indication and regulatory milestones will be disclosed.